Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE ‐023 study-Reference-Cited by-同舟云学术

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE ‐023 study

Published:2019-05-15 Issue:5 Volume:186 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mateos Maria‐Victoria¹^ORCID,Orlowski Robert Z.²,Ocio Enrique M.³^ORCID,Rodríguez‐Otero Paula⁴,Reece Donna⁵,Moreau Philippe⁶^ORCID,Munshi Nikhil⁷,Avigan David E.⁸,Siegel David S.⁹,Ghori Razi¹⁰,Farooqui Mohammed Z. H.¹⁰,Marinello Patricia¹⁰,San-Miguel Jesus⁴^ORCID

Affiliation:

1. Complejo Asistencial Universitario de Salamanca/IBSAL & Centro de Investigación del Cáncer (IBMCC‐CSIC‐USAL) Salamanca Spain

2. The University of Texas MD Anderson Cancer Center Houston TX USA

3. Hospital Universitario Marqués de Valdecilla (IDIVAL) & University of Cantabria Santander Spain

4. Clinica Universidad de Navarra CIMA, IDISNA, CIBERONC Pamplona Spain

5. Princess Margaret Cancer Centre Toronto ON Canada

6. University Hospital Hotel‐Dieu Nantes France

7. Dana‐Farber Cancer Institute Boston MA USA

8. Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA

9. John Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ USA

10. Merck & Co, Inc Kenilworth NJ USA

Funder

Merck Sharp and Dohme

Merck

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15946

Reference9 articles.

1. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

2. The ASCO Post(2017)FDA places clinical hold on three studies evaluating pembrolizumab in multiple myeloma.http://www.ascopost.com/News/57813. Accessed 5 February 2019.

3. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

4. International uniform response criteria for multiple myeloma

5. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies;Stem Cell Research & Therapy;2024-08-13

2. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

4. The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P‐selectin glycoprotein ligand‐1 (PSGL‐1) gene polymorphism in multiple myeloma;Molecular Carcinogenesis;2024-07-02

5. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma;Cancer;2024-04-17